Skip to main content
Premium Trial:

Request an Annual Quote

Data Analysis Startup LatchBio Closes $28M Series A Round

NEW YORK – Biological data analysis firm LatchBio said Thursday that it has closed a Series A funding round worth $28 million. Coatue and Lux Capital led the round, with participation from new investors Hummingbird Ventures and Caffeinated Capital, plus existing investors Haystack and Fifty Years.

San Francisco-based LatchBio offers a web-based technology platform for researchers to store, analyze, and visualize multiomics data without the need for programming or other technical skills. The LatchBio platform features an automated software development kit to create interfaces to bioinformatics pipelines and visualization tools including CRISPResso2, DeepMind's AlphaFold 2, and various RNA sequencing processors.

Customers include the Innovative Genomics Institute, Bit.Bio, and Eligo Bioscience.

"We remain obsessively focused on building a platform that hosts the best biocomputing workflows and other tools that scientists love to use and that enable them to accelerate scientific progress," Alfredo Andere, cofounder and CEO of LatchBio, said in a statement.

"The datasets generated by today's scientific experiments are growing at an exponential rate, but many biologists lack the computational tools they need to rapidly analyze and iterate using the results of their experiments," added Coatue General Partner David Cahn. "Coatue looks forward to supporting LatchBio’s ambition to create the necessary infrastructure to hasten the pace of discovery and translational research — and importantly, help get more lifesaving therapies into the clinic."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.